MGRX

Mangoceuticals, Inc.
CAPPED RATING

Mangoceuticals, Inc. (MGRX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (F). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B-
Factor Score 2.9 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.3
Rev Growth YoY -59.1%
Gross Margin 54.4%
Price Return 3M -65.4%
Price Return 12M -89.2%
Catalyst Signal 0.00
Market Cap $4.1M
TTM Revenue $315.2K
Price / Sales 13.0
ROE -95.1%

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) F (0.6) C (2.5) D (1.2) C+ (2.6) C- (2.0)
2026-11-06 B- (2.9) F (0.5) C+ (2.5) C- (1.9) C+ (2.7) C- (2.1)
2026-10-30 B- (2.9) F (0.5) C+ (2.6) C- (1.9) C+ (2.7) C- (2.1)
2026-10-23 B- (2.9) F (0.5) C+ (2.6) D+ (1.6) C+ (2.6) C- (2.0)
2026-10-16 B- (2.9) F (0.5) C+ (2.6) C- (2.1) C+ (2.6) C- (2.1)
Page 1 of 4